The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KRYS | +76.71% | +313.16% | +32.81% | +2,553% |
| S&P | +15.49% | +82.14% | +12.74% | +178% |
Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. Krystal was founded by Krish Krishnan & Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Here are the five best biotech ETFs to invest in right now.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $97.80M | 16.6% |
| Gross Profit | $92.14M | 21.8% |
| Gross Margin | 94.21% | 4.0% |
| Market Cap | $5.11B | -2.3% |
| Market Cap / Employee | $18.58M | 0.0% |
| Employees | 275 | 0.0% |
| Net Income | $79.37M | 192.0% |
| EBITDA | $42.98M | 18.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $392.60M | 5.0% |
| Accounts Receivable | $129.63M | 33.2% |
| Inventory | 37.6 | 102.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $7.81M | 26.3% |
| Short Term Debt | $1.70M | 31.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 17.90% | 12.0% |
| Return On Invested Capital | -7.63% | 3.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $37.96M | -34.3% |
| Operating Free Cash Flow | $39.66M | -32.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 52.43 | 43.42 | 27.96 | 26.48 | -74.29% |
| Price to Book | 5.09 | 5.49 | 4.03 | 4.91 | -21.23% |
| Price to Sales | 16.11 | 16.15 | 11.38 | 14.11 | -37.38% |
| Price to Tangible Book Value | 5.09 | 5.49 | 4.03 | 4.91 | -21.23% |
| Price to Free Cash Flow TTM | 39.28 | 41.65 | 22.05 | 31.80 | -66.07% |
| Enterprise Value to EBITDA | 95.22 | 126.38 | 83.65 | 105.74 | -20.80% |
| Free Cash Flow Yield | 2.5% | 2.4% | 4.5% | 3.1% | 194.76% |
| Return on Equity | 10.3% | 13.9% | 15.6% | 19.7% | 208.12% |
| Total Debt | $7.26M | $9.66M | $9.68M | $9.51M | 27.22% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
